The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
The negative association between TP53 mutations and clinical outcomes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has been widely studied; however, the impact of these aberrations in myeloproliferative neoplasms (MPNs) has not been widely studied. In this interview, Akriti Jain, MD, Cleveland Clinic, Cleveland, Ohio, discusses the prognostic implications of the timing of TP53 mutation acquisition in MPNs and MDS/MPN overlap syndromes, highlighting that later emergence of the mutation in the disease course is associated with significantly poorer survival outcomes. Dr Jain emphasizes the potential importance of considering the timing of TP53 acquisition for improved risk stratification and clinical decision-making. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
